Metagenomi (MGX) Director Eric Bjerkholt Receives 21,000-Share Award

What Happened
Eric Bjerkholt, a director of Metagenomi Therapeutics, was granted a derivative award covering 21,000 shares on June 9, 2026. The Form 4 reports the acquisition at $0.00 (no cash paid at grant). This filing reflects a compensation grant (award of an option), not a market purchase or sale.

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-11.
• Transaction type: Award/Grant (derivative) — 21,000 shares; reported price $0.00; acquisition value $0.
• Shares owned after transaction: Not specified in this Form 4.
• Vesting note: The shares/options vest on the earlier of (i) the one-year anniversary of the grant date or (ii) the Company’s 2027 annual meeting, subject to Bjerkholt’s continued service.
• Filing timeliness: Filed within the typical 2-business-day window (no late filing indicated).

Context
This was a compensatory option grant that vests in the future; it is not an option exercise or an immediate sale. Such grants are common for directors and reflect compensation arrangements rather than a direct market signal to buy or sell the stock.